We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




V.I. Technologies to Merge with Panacos Pharmaceuticals

By HospiMedica staff writers
Posted on 10 Jun 2004
In a move to create a new company with a strong pipeline of products, Panacos Pharmaceuticals, Inc.(Gaithersburg, MD, USA) and V.I. More...
Technologies, Inc. (Vitex, Watertown, MA, USA), have agreed to merge. Vitex is developing innovative anti-infective technologies to enhance blood safety.

Under the terms of the transaction, Vitex will issue 25 million common shares in exchange for all outstanding Panacos shares upon the close of the transaction. Vitex will issue up to an additional 20 million common shares to Panacos shareholders upon the successful completion of near-term clinical milestones for PA-457, a new HIV maturation inhibitor.

The merged company will have a strong pipeline of products for serious infectious diseases. These include Vitex's Inactine technology, currently in phase 3 clinical testing for the inactivation of pathogens in red blood cells, and Panacos' pipeline of novel therapeutic small-molecule antiviral drugs that include PA-457, currently in phase 1 clinical testing.

Samuel K. Ackerman, M.D., currently chairman of Vitex and chairman and acting CEO of Panacos, will be chairman and CEO of the combined company, which will use the V.I. Technologies and Vitex names. "Combining the technology platforms of Vitex and Panacos will create a dynamic new anti-infectives company developing innovative pharmaceutical products addressing major global healthcare problems,” commented Dr. Ackerman. "Clinical-stage products in the combined company will initially address markets exceeding U.S.$8 billion and have strong competitive and intellectual property positions.”




Related Links:
Panacos
Vitex

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gastrointestinal Panel
Xpert® GI Panel
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.